Pharmacist Law | THC / CBD Written 1h

The state and federal regulatory status of medical marijuana, tetrahydrocannabinol (THC), and cannabidiol (CBD) is conflicting and ever-changing. This course guides pharmacists on how to interpret these conflicting regulations as they shift, as well as provides the FDA’s perspective on the legality of CBD as an unapproved drug.

Learning Objectives

Upon successful completion of this knowledge-based CPE course, pharmacists should be able to:
1. Discuss the conflict of laws between states that have legalized marijuana for medical or recreational use, and the federal government approach that continues to classify marijuana as an illegal drug.
2. Review implications of the 2018 Farm Bill that legalized the distribution of CBD under some circumstances.
3. Explain the FDA perspective on the legality of cannabidiol (CBD) as an unapproved new drug.

Faculty

David Brushwood, RPh, JD, FAPhA

Senior Lecturer, The University of Wyoming School of Pharmacy
Pharmacy Law Content Developer, CEimpact

Disclosures:

David Brushwood has no relevant financial relationships with ineligible companies to disclose.

Course Details